Single-cell study for resectable pancreatic cancer patients
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses a special technique called single-cell sequencing to study pancreatic cancer cells from patients whose tumors can be surgically removed or are on the edge of being removable. Participation may help researchers understand the disease better and could guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years old.
- Have pancreatic cancer that can be surgically removed or is borderline removable, based on tests and imaging.
- Have not received any anti-cancer treatment before.
- At least one tumor that can be measured on scans.
- Good overall health and ability to perform daily activities (ECOG score 0 or 1).
- Not currently in any other clinical trial.
- Willing to sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a method that analyzes your tumor's genes and grows a mini-tumor in a dish to find which drugs might work best for your metastatic pancreatic cancer. It aims to improve treatment choices by using these personalized tests.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This trial studies a new blood test that looks for cancer-specific immune cells after surgery for pancreatic cancer. It aims to see if the test can detect any remaining cancer cells earlier than standard methods, which could help guide further treatment decisions.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.